At Dassault Systèmes, we are fueled by the profound belief that virtual worlds extend and improve the real world, because they are spaces where we can represent and experiment. Since 1981, we have been instrumental in helping companies sustainably innovate products. In parallel, our ambition to harmonize product, nature and life has led us to develop a new understanding of life and nature. Back in February, we announced an evolution in our company’s purpose to put our focus on moving ‘from things to life.’ This is possible today because we’re capable of applying the knowledge and know-how we acquired in the non-organic world to the organic – living – world.
Imagine being able to understand, model, search, test, and treat a human body as precisely, safely and effectively as we already can today for a plane, a car or a building. We can transform how people are cured and help them live a better life. This is what we call the virtual twin, and what Scientific American just this week named one of the top 10 emerging technology twins of 2020.
In its article “Virtual Patients Could Revolutionize Medicine: Replacing humans with digital simulations could make clinical trials faster and safer“, Scientific American explores the potential benefits of in silico medicine – the testing of drugs and treatments on virtual organs or body systems to predict how a real person will respond to the therapies. This can result in faster and less expensive treatment options and greatly reduce the number of live human subjects.